CVE-2023-37292

HGiga iSherlock - Command Injection

Description

Improper Neutralization of Special Elements used in an OS Command ('OS Command Injection') vulnerability in HGiga iSherlock 4.5 (iSherlock-user modules), HGiga iSherlock 5.5 (iSherlock-user modules) allows OS Command Injection.This issue affects iSherlock 4.5: before iSherlock-user-4.5-174; iSherlock 5.5: before iSherlock-user-5.5-174.

Remediation

Solution:

  • iSherlock 4.5: update iSherlock-user module version to 至 4.5-174(MSR45) or later version iSherlock5.5: update iSherlock-user module version to 至 5.5-174(MSR55) or later version

Category

9.8
CVSS
Severity: Critical
CVSS 3.1 •
EPSS 0.34%
Third-Party Advisory org.tw
Affected: HGiga iSherlock 4.5
Affected: HGiga iSherlock 5.5
Published at:
Updated at:

References

Link Tags
https://www.twcert.org.tw/tw/cp-132-7239-8fc29-1.html third party advisory

Frequently Asked Questions

What is the severity of CVE-2023-37292?
CVE-2023-37292 has been scored as a critical severity vulnerability.
How to fix CVE-2023-37292?
To fix CVE-2023-37292: iSherlock 4.5: update iSherlock-user module version to 至 4.5-174(MSR45) or later version iSherlock5.5: update iSherlock-user module version to 至 5.5-174(MSR55) or later version
Is CVE-2023-37292 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2023-37292 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2023-37292?
CVE-2023-37292 affects HGiga iSherlock 4.5, HGiga iSherlock 5.5.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.